Shah Jatin
Known title: EVP, Chief Medical OfficerCIK: 0001782186
Associated companies
Transaction History
| KPTI | ▼ Sell | Open Market | 1,306 | $16K | 2/17/2022 | View on chart |
| KPTI | ▼ Sell | Open Market | 1,704 | $17K | 2/7/2022 | View on chart |
| KPTI | ▼ Sell | Open Market | 1,306 | $16K | 2/17/2022 | View on chart |
| KPTI | ▼ Sell | Open Market | 1,704 | $17K | 2/7/2022 | View on chart |
We use analytics to understand how market-wall is used. No personal data is sold.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 2, 2026
Karyopharm Reports Inducement Grant Under Nasdaq Rule
Karyopharm Therapeutics disclosed an inducement grant made under Nasdaq Listing Rule 5635(c)(4). This type of disclosure is typically required when a company offers equity compensation to a new employee or consultant to induce them to join the firm. The announcement is a standard corporate compliance update rather than a change in business operations or financial results.
Karyopharm Reports Inducement Grant Under Nasdaq Rule. Karyopharm Therapeutics disclosed an inducement grant made under Nasdaq Listing Rule 5635(c)(4). This type of disclosure is typically required when a company offers equity compensation to a new employee or consultant to induce them to join the firm. The announcement is a standard corporate compliance update rather than a change in business operations or financial results.